Xigduo: dapagliflozin plus metformin for T2DM

Xigduo, a combination of dapagliflozin and metformin, is licensed as second-line therapy in patients with type 2 diabetes. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse events and Drs Claire McCourt and Frank Joseph discuss its place in therapy.

Xigduo dapagliflozin plus metformin for T2DM

Add yours ↓
Web design and marketing agency Leamington Spa